Advances On the Biosimilar Litigation Battlefield

 
• By Brenda Sandburg

A look at the evolution of litigation, from Amgen's 'bold' at-risk launch of Herceptin and Avastin biosimilars to the jump in settlements, new battles over manufacturing information and an expected petition to the Supreme Court.

Medieval battle scene with cavalry and infantry on chessboard. Chess board game concept of business ideas and competition and strategy ideas Chess figures on a dark background with smoke and fog. - Image
Biosimilar makers and innovators are fighting over host of issues.

More from Biosimilars

More from Biosimilars & Generics